文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

阿鲁巴耐药HIV传播率高,近半数新诊断患者对WHO推荐一线方案敏感性降低

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该研究对2010-2015年阿鲁巴104例新诊断未治疗HIV感染者进行耐药检测,33%感染耐药变异株,2015年NNRTI耐药率达45%且均基于K103N突变。系统发育分析显示K103N毒株经至少6次独立传播引入,导致WHO推荐一线NNRTI方案病毒学失败率升高。

要点

  • 阿鲁巴新诊断HIV感染者中33%携带耐药变异株,2015年NNRTI耐药率达45%。
  • K103N突变是主要耐药机制,经至少6次独立传播从周边国家引入。
  • K103N存在时WHO推荐一线NNRTI方案病毒学失败率更高。

核心结论

  • 阿鲁巴耐药HIV流行率已升至警示水平,损害WHO推荐一线方案疗效。
  • 加勒比地区可能面临NNRTI耐药HIV未被识别的上升,因WHO倡导的监测有限。

研究设计与样本

  • 调查纳入2010-2015年阿鲁巴所有接受耐药检测的HIV感染者。
  • 基线耐药检测覆盖104例新诊断未治疗个体,占同期全部新诊断者的54%。
  • 采用WHO标准判定传播性HIV耐药,用系统发育分析研究传播动力学,并对部分基线样本行NGS再分析。

主要发现

  • 104例中86%为男性,39%为外国出生,22%诊断时已患艾滋病。
  • 33%(95% CI:24-42%)感染耐药HIV变异株。
  • 2015年NNRTI耐药患病率达45%(95% CI:27-64%),均基于K103N突变。
  • NGS未发现常规耐药检测之外的额外少数K103N变异。
  • 携带K103N的毒株经至少6次独立传播、与周边国家流行病学关联,引入未治疗人群。

临床怎么用

  • 在阿鲁巴等加勒比高流行区,新诊断HIV感染者启动一线NNRTI方案前应考虑耐药检测。
  • K103N流行率高的地区需评估WHO推荐一线NNRTI方案的适用性。

局限性

  • 耐药检测仅覆盖54%的新诊断个体,可能存在选择偏倚。
  • NGS仅对部分基线样本再分析,未系统评估少数变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Western countries emergence of human immunodeficiency virus (HIV) drug resistance has tremendously decreased, and transmission of drug resistance has merely stabilized in recent years. However, in many endemic settings with limited resources rates of emerging and transmitted drug resistance are not regularly assessed. METHODS: We performed a survey including all HIV-infected individuals who received resistance testing in 2010-2015 in Aruba, a highly endemic HIV area in the Caribbean. Transmitted HIV drug resistance was determined using World Health Organization (WHO) criteria. Transmission dynamics were investigated using phylogenetic analyses. In a subset, baseline samples were re-analyzed using next generation sequencing (NGS). RESULTS: Baseline resistance testing was performed in 104 newly diagnosed untreated individuals (54% of all newly diagnosed individuals in 2010-2015): 86% were men, 39% were foreign-born, and 22% had AIDS at diagnosis. And 33% (95% CI: 24-42%) was infected with a drug-resistant HIV variant. The prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (95% CI: 27-64%) in 2015, all based on the prevalence of mutation K103N. NGS did not demonstrate additional minority K103N-variants compared to routine resistance testing. K103N-harboring strains were introduced into the therapy-unexposed population via at least 6 independent transmissions epidemiologically linked to the surrounding countries. Virological failure of the WHO-recommended first-line NNRTI-based regimen was higher in the presence of K103N. CONCLUSIONS: The prevalence of resistant HIV in Aruba has increased to alarming levels, compromising the WHO-recommended first-line regimen. As adequate surveillance as advocated by the WHO is limited, the Caribbean region could face an unidentified rise of NNRTI-resistant HIV.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hofstra LM, Sánchez Rivas E, Nijhuis M, et al. High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients. Clin Infect Dis. 2017. PMID: 28329390. doi:10.1093/cid/cix056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。